Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01074710 · ClinicalTrials.gov registry record · Phase 1

Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers

A Phase 1 study of Gastroparesis, sponsored by Otsuka Pharmaceutical Co..

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT01074710: Completed Phase 1 study of Gastroparesis, sponsored by Otsuka Pharmaceutical Co..

NCT01074710 is a Phase 1 study of Gastroparesis that has completed, run by Otsuka Pharmaceutical Co.. The registered enrollment target is 8 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01074710, a Phase 1 study of Gastroparesis, has completed, sponsored by Otsuka Pharmaceutical Co..

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and establish the pharmacokinetic (PK) profile of C13-URA in healthy volunteers

Primary Outcome

Pharmacokinetic endpoints will include apparent clearance (CL/F), AUCt, AUC∞, Cmax, tmax, and t1/2,Z for 13C-uracil and its metabolites. The PK linearity and correlation between plasma concentration and urine excretion will be evaluated. Expired 13CO2 concentrations (Δ13C) will be converted to 13CO2-excretion(% dose/hr) to assess breath PK parameters (AUCt, AUC∞, Cmax, tmax, λZ, and t1/2,Z).

Conditions Studied

Interventions

  • DRUG [2-13C] uracil
  • DRUG [2-13C] uracil, placebo

Study Locations (1)

Wisconsin

  • Covance Clinical Pharmacology, Inc. - Madison

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2010-02
Est. Completion 2010-05
Phase Phase 1
Otsuka Pharmaceutical Co.

2 total trials

What the finished NCT01074710 record still lists

NCT01074710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which [2-13C] uracil is the first listed.

NCT01074710 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01074710 about?

NCT01074710 is a clinical study titled "Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers". The purpose of this study is to evaluate the safety and establish the pharmacokinetic (PK) profile of C13-URA in healthy volunteers

What is the current status of trial NCT01074710?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-02. Estimated completion is 2010-05.

What conditions does trial NCT01074710 study?

This clinical trial studies the following conditions: Gastroparesis.

What interventions are being tested in trial NCT01074710?

The interventions under investigation include: [2-13C] uracil (DRUG), [2-13C] uracil, placebo (DRUG).

Who is sponsoring clinical trial NCT01074710?

This trial is sponsored by Otsuka Pharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01074710 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01074710's enrollment target sits among peer trials

8 44th of 44 higher than 1 of 44 other Gastroparesis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01074710, the US trial registry maintained by the National Library of Medicine. NCT01074710 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.